Europol, European Monitoring Centre for Drugs and Drug Addiction. (2014) EMCDDA–Europol Joint report on a new psychoactive substance: methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone). Lisbon: European Monitoring Centre for Drugs and Drug Addiction & Europol.
Preview | Title | Contact |
---|---|---|
PDF (Report on a new psychoactive substance: methoxetamine)
- Published Version
681kB |
The EMCDDA–Europol Joint Report on new psychoactive substance methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the EMCDDA and Europol concluded that sufficient information had been accumulated to merit the production of a Joint Report on methoxetamine as stipulated by Article 5.1 of the Decision.
Common names or codenames that have also been reported are: 3-MeO-2-Oxo-PCE, MXE, MXE100 and metoksetamiini (Finnish).
The following street names have also been reported: ‘MXE’, ‘Mexxy’, ‘M-ket’, ‘MEX’, ‘Kmax’, ‘Special M’, ‘MA’, ‘legal ketamine’, ‘Minx’, ‘Jipper’ and ‘Roflcoptr’.
Finally, the following ‘legal high’ product names have been associated with methoxetamine: ‘Kwasqik’, ‘Hypnotic’, ‘Panoramix’, ‘Magic’, ‘Lotus’, ‘Special K’ and ‘X’.
B Substances > New (novel) psychoactive substances > Aminoindanes / Arylalkylamines / Arylcyclohexylamines
E Concepts in biomedical areas > Pharmacology and toxicology
J Health care, prevention, harm reduction and treatment > Risk and needs assessment > Risk assessment
L Social psychology and related concepts > Legal availability or accessibility
VA Geographic area > Europe
Repository Staff Only: item control page